ClinicalTrials.gg

Program

LSD1 Inhibitor EXS74539

Its studies are mostly in Small Cell Lung Carcinoma, led by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals.

Furthest: phase 1, since Mar 27, 20261 company-led study, 1 open or runningNext primary completion: Mar 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals11 open or runningphase 1since Mar 27, 2026Mar 27, 2026Mar 2029phase 1 · NCT07517198

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 27, 2026First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT07517198 · 40 planned · United States

Ahead

  1. Mar 2029Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT07517198

TargetBeta

KDM1A →read by rule
“An orally bioavailable reversible and central nervous system (CNS) penetrant inhibitor of lysine-specific demethylase 1 (LSD1; KDM1A), ”NCIt, by rule

Other programs on KDM1A

ProgramCompanyFurthest phaseStudies
bomedemstatMerckphase 311

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07517198Small Cell Lung Carcinoma · United States1RecruitingMar 202940

How it is read

Names in the registry

  • “EXS74539”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.